Anna Polakiewicz-Gilowska

603 total citations
16 papers, 52 citations indexed

About

Anna Polakiewicz-Gilowska is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Anna Polakiewicz-Gilowska has authored 16 papers receiving a total of 52 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 3 papers in Genetics. Recurrent topics in Anna Polakiewicz-Gilowska's work include Advanced Breast Cancer Therapies (5 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Breast Cancer Treatment Studies (3 papers). Anna Polakiewicz-Gilowska is often cited by papers focused on Advanced Breast Cancer Therapies (5 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Breast Cancer Treatment Studies (3 papers). Anna Polakiewicz-Gilowska collaborates with scholars based in Poland, Hungary and Austria. Anna Polakiewicz-Gilowska's co-authors include Michał Jarząb, Rafał Wiench, Małgorzata Kowalska, Ewa Chmielik, Wiesław Bal, Dariusz Lange, Barbara Bobek‐Billewicz, R. Tarnawski, Joanna Huszno and Aleksandra Krzywon and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Anna Polakiewicz-Gilowska

8 papers receiving 52 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Polakiewicz-Gilowska Poland 4 28 23 18 10 9 16 52
Kenneth B. Blankstein United States 4 26 0.9× 14 0.6× 31 1.7× 7 0.7× 7 0.8× 7 58
Kitti Maas Germany 4 16 0.6× 11 0.5× 17 0.9× 8 0.8× 12 1.3× 6 42
Kornelius Schulze Germany 4 14 0.5× 13 0.6× 15 0.8× 6 0.6× 17 1.9× 7 50
F. Marmé Germany 3 46 1.6× 19 0.8× 12 0.7× 6 0.6× 3 0.3× 4 58
Marie Osdoit France 5 39 1.4× 46 2.0× 8 0.4× 16 1.6× 13 1.4× 6 74
Olivia Lucas United Kingdom 3 12 0.4× 18 0.8× 10 0.6× 4 0.4× 8 0.9× 8 30
NL Busaidy United States 2 32 1.1× 11 0.5× 10 0.6× 6 0.6× 5 0.6× 2 67
Chengzhi Zhou China 5 40 1.4× 16 0.7× 47 2.6× 7 0.7× 10 1.1× 17 62
M. Maspoli-Conconi Switzerland 4 44 1.6× 10 0.4× 24 1.3× 25 2.5× 4 0.4× 6 67
Isma Rana United Kingdom 5 31 1.1× 29 1.3× 27 1.5× 22 2.2× 19 2.1× 9 61

Countries citing papers authored by Anna Polakiewicz-Gilowska

Since Specialization
Citations

This map shows the geographic impact of Anna Polakiewicz-Gilowska's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Polakiewicz-Gilowska with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Polakiewicz-Gilowska more than expected).

Fields of papers citing papers by Anna Polakiewicz-Gilowska

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Polakiewicz-Gilowska. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Polakiewicz-Gilowska. The network helps show where Anna Polakiewicz-Gilowska may publish in the future.

Co-authorship network of co-authors of Anna Polakiewicz-Gilowska

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Polakiewicz-Gilowska. A scholar is included among the top collaborators of Anna Polakiewicz-Gilowska based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Polakiewicz-Gilowska. Anna Polakiewicz-Gilowska is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Püsküllüoğlu, Mirosława, Anna Polakiewicz-Gilowska, Iveta Selingerová, et al.. (2025). 566P Effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer: A real-world retrospective cohort study from central Europe. Annals of Oncology. 36. S419–S419.
2.
3.
Polakiewicz-Gilowska, Anna, Manuela Las‐Jankowska, Michał Jarząb, et al.. (2025). Assessment of weight change and BMI as prognostic markers of survival outcomes in sacituzumab govitecan therapy for mTNBC in a Polish female cohort.. Journal of Clinical Oncology. 43(16_suppl).
4.
Püsküllüoğlu, Mirosława, Joanna Streb, Manuela Las‐Jankowska, et al.. (2025). Abstract P4-05-02: Strategies for premedication and neutropenia prophylaxis in sacituzumab govitecan treatment of patients with triple-negative breast cancer: multicenter insights. Clinical Cancer Research. 31(12_Supplement). P4–5. 1 indexed citations
5.
Polakiewicz-Gilowska, Anna, Manuela Las‐Jankowska, Michał Jarząb, et al.. (2025). Hemoglobin level and neutrophil-to-lymphocyte ratio as prognostic peripheral blood markers of survival outcomes in sacituzumab govitecan therapy for mTNBC in Polish female cohort.. Journal of Clinical Oncology. 43(16_suppl).
6.
Polakiewicz-Gilowska, Anna, Manuela Las‐Jankowska, Michał Jarząb, et al.. (2025). Weight change and BMI are not prognostic markers of survival outcomes in sacituzumab govitecan therapy for mTNBC in the Polish female cohort. Therapeutic Advances in Medical Oncology. 17. 22807840–22807840.
7.
Püsküllüoğlu, Mirosława, Manuela Las‐Jankowska, Joanna Streb, et al.. (2024). Sacituzumab Govitecan for Second and Subsequent Line Palliative Treatment of Patients with Triple-Negative Breast Cancer: A Polish Real-World Multicenter Cohort Study. Oncology and Therapy. 12(4). 787–801. 2 indexed citations
8.
Gabryś, Dorota, et al.. (2024). Efficacy of radiotherapy for bone metastasis in breast cancer patients treated with cyclin-dependent kinase 4/6 inhibitors. Radiotherapy and Oncology. 202. 110639–110639.
9.
Polakiewicz-Gilowska, Anna, Andrea d’Amico, Ewa Chmielik, et al.. (2024). The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting. Frontiers in Oncology. 14. 1454844–1454844.
10.
Polakiewicz-Gilowska, Anna, et al.. (2024). Tailoring advanced breast cancer treatment after cyclin-dependent kinase 4/6 inhibitors progression - real-world data analysis. Frontiers in Oncology. 14. 1408664–1408664. 1 indexed citations
11.
Gabryś, Dorota, Anna Polakiewicz-Gilowska, Alexander Jorge Cortez, et al.. (2023). Safety and Feasibility of Radiation Therapy Combined with CDK 4/6 Inhibitors in the Management of Advanced Breast Cancer. Cancers. 15(3). 690–690. 11 indexed citations
12.
Jarząb, Michał, et al.. (2023). Efficacy of CDK 4/6 Inhibitors and Radiotherapy in Breast Cancer Patients with Brain Metastases. Journal of Clinical Medicine. 12(5). 2044–2044. 4 indexed citations
13.
Jarząb, Michał, Ewa Chmielik, Małgorzata Kowalska, et al.. (2019). Association of breast cancer grade with response to neoadjuvant chemotherapy assessed postoperatively. Polish Journal of Pathology. 70(2). 91–99. 18 indexed citations
14.
Polakiewicz-Gilowska, Anna, et al.. (2015). Interstitial pneumonia during treatment with rituximab. 5(1). 16–20.
15.
Wiench, Rafał, et al.. (2014). Necrotizing sialometaplasia of the palatal mucosa in patient with history of anorexia: Review and case report. American Journal of Otolaryngology. 35(3). 400–401. 12 indexed citations
16.
Nowara, Elżbieta, et al.. (2012). Chemotherapy for gastric cancer patients – time for personalization in medicine?. Współczesna Onkologia. 1(1). 86–89. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kenneth B. Blankstein Breakdown of academic impact, for papers by Kitti Maas Breakdown of academic impact, for papers by Kornelius Schulze Breakdown of academic impact, for papers by F. Marmé Breakdown of academic impact, for papers by Marie Osdoit Breakdown of academic impact, for papers by Olivia Lucas Breakdown of academic impact, for papers by NL Busaidy Breakdown of academic impact, for papers by Chengzhi Zhou Breakdown of academic impact, for papers by M. Maspoli-Conconi Breakdown of academic impact, for papers by Isma Rana
Rankless by CCL
2026